

Primary Driver In The Vaxneuvance Market 2025: Impact Of High Pneumonia Prevalence On Vaccine Demand

Vaxneuvance Global Market Report 2025

– Market Size, Trends, And Global
Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, March 14, 2025
/EINPresswire.com/ -- Updated 2025
Market Reports released recently highlight trends and forecasts to 2034,



offering your competitive edge today by buying early!

Is the <u>Vaxneuvance Market</u> Poised for Significant Expansion?

The Vaxneuvance market has experienced rapid growth in recent years, with projections

indicating continued expansion.

"

The vaxneuvance market size is expected to see XX (FCAGR) in the next few years. It will grow to \$XX million in 2029 at a compound annual growth rate (CAGR) of XX%."

The Business Research
Company

□In 2024, the market size is anticipated to reach \$XX million.

☐By 2025, it is expected to grow further to \$XX million, reflecting a compound annual growth rate (CAGR) of XX%. ☐Key factors behind this historical growth include the increasing prevalence of pneumococcal diseases, a rising aging population, favorable regulatory approvals, increased government funding for vaccinations, and the impact of travel and globalization.

Get Your Free Sample Market Report:

https://www.thebusinessresearchcompany.com/sample.as

px?id=20428&type=smp

What Are the Critical Drivers Anticipated to Propel the <u>Vaxneuvance Market Growth</u>? Looking ahead, the market is set to witness an even stronger growth trajectory:

By 2029, the market is projected to reach \$XX million, growing at a XX% CAGR.

The expected drivers for this expansion include a rise in chronic illnesses, increasing antimicrobial resistance, a surge in respiratory infections among children, a growing

immunocompromised population, and higher healthcare investments.

□Emerging trends in the forecast period include needle-free vaccine delivery systems, advancements in cold-chain technologies, Al-powered supply chain optimization, integration with digital health records for immunization tracking, and innovative adjuvant systems to enhance immune response.

What Are the Key Growth Drivers of the Vaxneuvance Market?

A major factor propelling the Vaxneuvance market forward is the increasing prevalence of pneumonia. This infectious disease, which inflames the air sacs in one or both lungs, leads to symptoms such as fever, coughing, and breathing difficulties. The rise in pneumonia cases is driven by viral and bacterial infections, weakened immune systems, air pollution, and an aging population, all of which heighten susceptibility to respiratory diseases.

Vaxneuvance plays a crucial role in combating pneumonia caused by 15 strains of Streptococcus pneumoniae, significantly reducing the risk of severe infections and related complications.

Order Your Market Report Now for Quick Access:

https://www.thebusinessresearchcompany.com/report/vaxneuvance-global-market-report

Who Are the Leading Companies in the Vaxneuvance Market?

Key players in the Vaxneuvance market include Merck & Co. Inc., a prominent name in the healthcare industry. A major trend shaping the market is the expansion of vaccine indications, allowing broader patient coverage and addressing unmet medical needs.

For instance, in June 2022, Merck & Co. Inc. secured an expanded approval from the United States Food and Drug Administration (FDA) for Vaxneuvance, allowing its use in children aged 6 weeks to 17 years. This approval strengthens the vaccine's role in preventing invasive pneumococcal diseases across multiple age groups.

How Is the Vaxneuvance Market Segmented?

The Vaxneuvance market is categorized based on the following segments:

□By Indication: Pneumonia, Meningitis, Sepsis, Bacteremia, Otitis Media

By Distribution Channel: Pharmacies, Hospitals

☐By End User: Adults, Children, Geriatric Population

Which Regions Are Leading in the Vaxneuvance Market?

Geographically, North America emerged as the largest regional market in 2024. The report also covers regions including Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa.

Browse for more similar reports-

H1N1 Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/h1n1-vaccine-global-market-report Pediatric Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pediatric-vaccine-global-market-report Cancer Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Learn More About The Business Research Company

The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

Contact Us:

The Business Research Company

Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc info

YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxlCpgmyFQ

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

Facebook

Χ

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/793475715

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.